The latest price target for Edesa Biotech (NASDAQ:EDSA) was reported by HC Wainwright & Co. on August 20, 2024. The analyst firm set a price target for $21.00 expecting EDSA to rise to within 12 months (a possible 854.55% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Edesa Biotech (NASDAQ:EDSA) was provided by HC Wainwright & Co., and Edesa Biotech reiterated their buy rating.

There is no last upgrade for Edesa Biotech

There is no last downgrade for Edesa Biotech.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edesa Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edesa Biotech was filed on August 20, 2024 so you should expect the next rating to be made available sometime around August 20, 2025.

While ratings are subjective and will change, the latest Edesa Biotech (EDSA) rating was a reiterated with a price target of $21.00 to $21.00. The current price Edesa Biotech (EDSA) is trading at is $2.20, which is out of the analyst’s predicted range.